Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Raymond James Initiates Coverage On Agios Pharmaceuticals with Market Perform Rating

Raymond James analyst Danielle Brill initiates coverage on Agios Pharmaceuticals (NASDAQ:AGIO) with a Market Perform rating.

byBenzinga Newsdesk

July 1, 2021

1 minute read

Raymond James analyst Danielle Brill initiates coverage on Agios Pharmaceuticals (NASDAQ:AGIO) with a Market Perform rating.

Morgan Stanley Maintains Underweight on C3.ai, Lowers Price Target to $45

By Benzinga Newsdesk

Today, 10:28 AM

Morgan Stanley analyst Sanjit Singh maintains C3.ai (NYSE:AI) with a Underweight and lowers the price target from $62 to $45.

Columbia Care’s Preliminary Full Year Revenue Grows 156% YoY To $460M, Reports Positive Adjusted EBITDA

By Nina Zdinjak

Today, 10:28 AM

Columbia Care Inc. (NEO:CCHW) (CSE:CCHW) (OTCQX: CCHWF) (FSE: 3LP) released Monday preliminary results for the full year ended December 31, 2021, reporting revenue of $460 million, up by 156% from 2020.

CCHWF

Keybanc Upgrades FMC to Overweight, Announces $122 Price Target

By Benzinga Newsdesk

Today, 10:28 AM

Keybanc analyst Aleksey Yefremov upgrades FMC (NYSE:FMC) from Sector Weight to Overweight and announces $122 price target.

FMC

Why Diamondback Energy’s Stock Is Trading Higher Today

By Randy Elias

Today, 10:28 AM

Diamondback Energy, Inc. (NASDAQ: FANG) shares are trading higher after the company reported better-than-expected Q2 EPS and sales results.

FANG

Raymond James Initiates Coverage On Agios Pharmaceuticals with Market Perform Rating

Related Posts

Morgan Stanley Maintains Underweight on C3.ai, Lowers Price Target to $45

Columbia Care’s Preliminary Full Year Revenue Grows 156% YoY To $460M, Reports Positive Adjusted EBITDA

Keybanc Upgrades FMC to Overweight, Announces $122 Price Target

Why Diamondback Energy’s Stock Is Trading Higher Today